Outlook Therapeutics Inc

41O

Company Profile

  • Business description

    Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

  • Contact

    111 S. Wood Avenue
    Suite 100
    IselinNJ08852
    USA

    T: +1 609 619-3990

    E: LawrenceKenyon@outlooktherapeutics.com

    https://www.outlooktherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 September 2025

    Employees

    23

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,624.906.60-0.08%
CAC 407,788.1038.69-0.49%
DAX 4024,038.19188.30-0.78%
Dow JONES (US)42,098.70244.95-0.58%
FTSE 1008,726.0152.04-0.59%
HKSE23,258.31123.68-0.53%
NASDAQ19,100.9498.22-0.51%
Nikkei 22537,722.401.71-0.00%
NZX 50 Index12,362.26220.07-1.75%
S&P 5005,888.5532.99-0.56%
S&P/ASX 2008,396.9010.70-0.13%
SSE Composite Index3,339.930.76-0.02%

Market Movers